<SEC-DOCUMENT>0000950103-16-010117.txt : 20160108
<SEC-HEADER>0000950103-16-010117.hdr.sgml : 20160108
<ACCEPTANCE-DATETIME>20160108163030
ACCESSION NUMBER:		0000950103-16-010117
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160108
DATE AS OF CHANGE:		20160108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHARLES RIVER LABORATORIES INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001100682
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				061397316
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15943
		FILM NUMBER:		161333587

	BUSINESS ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887
		BUSINESS PHONE:		781-222-6000

	MAIL ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES HOLDINGS INC
		DATE OF NAME CHANGE:	19991208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dp62451_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<hr align="center" noshade size="1" style="color: Black; width: 15%; margin-top: 3pt; margin-bottom: 3pt">
<p style="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 8-K</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<hr align="center" noshade size="1" style="color: Black; width: 15%; margin-top: 3pt; margin-bottom: 3pt">
<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 11pt"><b>Pursuant
to Section 13 or 15(d) of the</b><br>
<b>Securities Exchange Act of 1934</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 11pt">&nbsp;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 11pt"><b>Date of
report (Date of earliest event reported): January 6, 2016</b></font></p>

<br>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<hr align="center" noshade size="1" style="color: Black; width: 15%; margin-top: 3pt; margin-bottom: 3pt">
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 10pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>CHARLES
    RIVER LABORATORIES INTERNATIONAL, INC.</b></font></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">as Specified in Charter)</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="font-size: 11pt; width: 34%">&nbsp;</TD>
    <td style="font-size: 10pt; text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <td style="font-size: 11pt; width: 34%">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of Incorporation)</FONT></TD>
    <td style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-15943</B></FONT></TD>
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>06-1397316</B></FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="background-color: white">
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>251 Ballardvale Street</B></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Wilmington, Massachusetts</b>&nbsp;</p></TD>
    <td style="vertical-align: top; font-size: 11pt">&nbsp;</TD>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>01887</B></FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="font-size: 11pt">&nbsp;</TD>
    <td style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s telephone number, including area code:&nbsp;&nbsp;<B>(781) 222-6000</B></FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 11pt">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
<tr style="vertical-align: top; background-color: white">
    <td colspan="3" style="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former Name or Former Address, if Changed Since Last Report)</FONT></TD></TR>
</TABLE>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&#9744;</font>&#9;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&#9744;</font>&#9;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&#9744;</font>&#9;
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&#9744;</font>&#9;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 6 , 2016, Charles River Laboratories
International, Inc. (&ldquo;<b>Charles River</b>&rdquo;), Pretzel Acquisition Corporation, a wholly-owned subsidiary of Charles
River (&ldquo;<b>Merger Sub</b>&rdquo;), WRH, Inc. (&ldquo;<b>WRH</b>&rdquo;) and American Capital Equity III, LP, in its capacity
as Stockholder&rsquo;s Representative, entered into an Agreement and Plan of Merger (the &ldquo;<b>Merger Agreement</b>&rdquo;)
pursuant to which and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will
be merged with and into WRH, with WRH surviving the merger as an indirect wholly-owned subsidiary of Charles River (the &ldquo;<b>Merger</b>&rdquo;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection and concurrently with Charles
River&rsquo;s entry into the Merger Agreement, (i) Charles River entered into a commitment letter (the &ldquo;<b>Commitment Letter</b>&rdquo;)
with J.P. Morgan Securities LLC and JPMorgan Chase Bank, N.A., pursuant to which Charles River&rsquo;s existing credit facility
will be expanded to make available to Charles River up to an additional $350 million in debt financing (the &ldquo;<b>Financing</b>&rdquo;),
and (ii) Charles River entered into a support agreement (the &ldquo;<b>Support Agreement</b>&rdquo;) with certain stockholders
of WRH pursuant to which such stockholders consented to the approval and adoption of the Merger Agreement, waived their statutory
appraisal rights and agreed to certain other covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><u>The Merger Agreement</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the Merger Agreement,
Charles River will acquire WRH for approximately $585 million in cash, subject to certain customary adjustments. Consummation of
the Merger is subject to customary closing conditions, including among other things: (i) the adoption and approval of the Merger
Agreement by WRH&rsquo;s stockholders (which has been obtained), (ii) the expiration or termination of the applicable waiting period
under the German Antitrust Laws, (iii) subject to the standards set forth in the Merger Agreement, the accuracy of representations
and warranties as of the closing and (iv) the absence of any developments that would reasonably be expected to have a material
adverse effect on WRH. Closing is expected to occur in the second quarter of 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Charles River and WRH each made customary
representations, warranties and covenants under the Merger Agreement. WRH has agreed to certain covenants, including among others,
that it will: (i) conduct its business in the ordinary course and refrain from taking certain actions until the consummation of
the Merger, (ii) use commercially reasonable efforts to consummate the Merger and (iii) provide evidence of the consent of its
stockholders to the Merger within two business days of the date of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger Agreement may be terminated
under specified circumstances, including if the Merger is not consummated on or before September 2, 2016 (the &ldquo;<b>Outside
Date</b>&rdquo;) for any reason other than the delay or the nonperformance of the terminating party. In the event the Merger Agreement
is terminated (i) as a result of an injunction, other governmental order or the withholding of an approval in each case pursuant
to applicable antitrust laws (ii) as a result of the failure of the Merger to occur on or before the Outside Date as a result of
the failure to obtain any approval under an applicable antitrust law or (iii) as a result of the breach of Charles River&rsquo;s
covenants with respect to antitrust matters, Charles River would be required to pay WRH a termination fee of $17.5 million which
will serve as WRH&rsquo;s sole and exclusive remedy upon such termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the Merger
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement,
which will be filed as an exhibit to Charles River&rsquo;s next periodic report due to be filed under the Securities Exchange Act
of 1934. The representations, warranties and covenants contained in the Merger Agreement have been made solely for the purposes
of the Merger Agreement and as of specific dates&#894; were solely for the benefit of the parties to the Merger Agreement&#894;
are not intended as statements of fact to be relied upon by Charles River stockholders or other security holders, but rather as
a way of allocating the risk between the parties in the event the statements therein prove to be inaccurate&#894; have been modified
or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the Merger
Agreement, which disclosures are not reflected in the Merger Agreement itself&#894; may no longer be true as of a given date&#894;
and may apply standards of materiality in a way that is different from what may be viewed as material by Charles River stockholders
or other security holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><u>The Commitment Letter</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 6, 2016, Charles River entered
into the Commitment Letter, pursuant to which J.P. Morgan Securities LLC and JPMorgan Chase Bank, N.A. (collectively, the &ldquo;<b>Committing
Parties</b>&rdquo;) committed to provide $350 million under a four-year incremental term loan facility (the &ldquo;<b>Incremental
Term Facility</b>&rdquo;) for the purpose of financing the Merger. In the alternative, Charles River may finance the Merger with
a new increased credit facility that would also refinance its existing credit facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Committing Parties&rsquo; commitment
to provide the Incremental Term Facility is subject to customary closing conditions more fully set forth in the Commitment Letter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the Commitment
Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Commitment Letter,
which will be filed as an exhibit to Charles River&rsquo;s next periodic report due to be filed under the Securities Exchange Act
of 1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b><u>The Support Agreement</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 6, 2016, concurrently with and
as an inducement for Charles River&rsquo;s entry into the Merger Agreement, American Capital Equity II, American Capital Equity
III and certain other stockholders of WRH, (collectively, the &ldquo;<b>Supporting Stockholders</b>&rdquo;) holding approximately
96% of the fully diluted capital stock of WRH, entered into the Support Agreement with Charles River. Pursuant to the Support Agreement,
the Supporting Stockholders agreed to: (i) vote all of their outstanding WRH stock in favor of the consummation of the Merger,
(ii) waive their statutory appraisal rights and (iii) agree to certain other covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each Supporting Stockholder has agreed
that, other than according to the terms of their respective Support Agreement, he or it will not (i) grant any proxies or enter
into any voting trust or other agreement or arrangement with respect to the voting of any WRH stock or (ii) subject to certain
limited exceptions, transfer, sell or otherwise dispose of any WRH ordinary or preferred stock during the term of the applicable
Support Agreement. The Support Agreement will terminate if the Merger Agreement is terminated prior to the closing of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the Support
Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Support Agreement, which
will be filed as an exhibit to Charles River&rsquo;s next periodic report due to be filed under the Securities Exchange Act of
1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><font style="font-weight: normal">On January
7, 2016, Charles River issued a press release announcing the transaction. A copy of the press release is attached hereto as Exhibit
99.1. The information being furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference into any filing
under the Securities Act of 1933, except as expressly set forth by reference in such filing.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%; text-decoration: underline; font-size: 10pt"><U>Exhibit Number</U></TD>
    <td style="width: 89%; text-decoration: underline; font-size: 10pt"><U>Title</U></TD></TR>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">99.1</TD>
    <td style="font-size: 10pt">Press release, dated January 7, 2016.</TD></TR>
</TABLE>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">Date:&nbsp;&nbsp;January 8, 2016</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td colspan="2"><font style="font-size: 10pt">CHARLES RIVER LABORATORIES INTERNATIONAL, INC.<BR>
    (Registrant)</font></TD>
    <td>&nbsp;</td></TR>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-size: 10pt">&nbsp;</font></TD>
    <td style="width: 38%"><font style="font-size: 10pt">&nbsp;</font></TD>
    <td style="width: 7%"><font style="font-size: 10pt">&nbsp;</font></TD>
    <td style="width: 3%"><font style="font-size: 10pt">By:</font></TD>
    <td style="width: 32%; border-bottom: Black 1pt solid"><font style="font-size: 10pt">/s/ Matthew Daniel</font></TD>
    <td style="width: 14%">&nbsp;</td></TR>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">Name:&#9;&nbsp;&nbsp;Matthew Daniel</font></TD>
    <td>&nbsp;</td></TR>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td><font style="font-size: 10pt">&nbsp;</font></TD>
    <td nowrap><font style="font-size: 10pt">Title:&#9;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Vice President, Deputy General<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counsel and Assistant Secretary</font></TD>
    <td>&nbsp;</td></TR>
</TABLE>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<p style="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp62451_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 91%; font-size: 12pt; vertical-align: middle; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>NEWS RELEASE</b></font></td>
    <TD STYLE="width: 9%; vertical-align: middle; text-align: left"><IMG SRC="logo.jpg" ALT="">&nbsp;</TD></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHARLES RIVER LABORATORIES TO ACQUIRE
WIL RESEARCH</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&ndash; Enhances Charles River&rsquo;s
Position as a Leading Global Early-Stage CRO &ndash;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&ndash; Transaction Expected
to be Accretive to Non-GAAP EPS by<BR>
At Least $0.20 in 2016 and $0.45-$0.50 in 2017 &ndash;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>WILMINGTON, MA, January 7,
2016</B> &ndash; Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive
agreement to acquire WIL Research for approximately $585 million in cash, subject to customary closing adjustments.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">WIL Research is a premier provider
of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial
chemical companies worldwide. Acquiring WIL Research will enhance Charles River&rsquo;s position as a leading global early-stage
contract research organization (CRO) by strengthening its ability to partner with global clients across the drug discovery and
development continuum.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">James C. Foster, Chairman, President,
and Chief Executive Officer of Charles River Laboratories, commented, &ldquo;In addition to meeting our disciplined acquisition
criteria, WIL Research is an exceptional strategic fit for Charles River because it incorporates the key attributes we require
in an acquisition: high-quality services, scientific expertise, complementary capabilities, and access to growing end markets.
The acquisition will also expand our geographic footprint, particularly in continental Europe, providing needed capacity to meet
current and future demand and enabling Charles River to provide a broader range of services proximate to our global clients.&rdquo;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;In addition to enhancing
our value proposition for clients, we believe that the acquisition of WIL Research will generate value for shareholders, driving
profitable revenue growth and non-GAAP earnings per share accretion of at least $0.20 in 2016 and $0.45 to $0.50 in 2017. We greatly
respect WIL Research&rsquo;s employees, its scientific capabilities, and the reputation it has built over 40 years since its founding,
and look forward to welcoming WIL Research to the Charles River family,&rdquo; Mr. Foster concluded.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Strategic Rationale</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The acquisition of WIL Research
will enhance Charles River&rsquo;s global footprint, scientific capabilities, and access to growing end markets, which provides
a compelling value proposition for both clients and shareholders.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Builds
                                         global scale</I></B><I> </I>&ndash; WIL Research will provide safety assessment infrastructure
                                         to support Charles River&rsquo;s current demand and future growth needs, with strategically
                                         located facilities to address global client requirements, including in continental Europe.
                                         In addition, the acquisition will strengthen Charles River&rsquo;s existing service offerings
                                         in different geographic regions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expands
                                         client base &ndash; </I></B>The acquisition aligns with Charles River&rsquo;s strategy
                                         to expand its biotechnology client base, its fastest-growing market segment. WIL Research
                                         has specialized in supporting this client segment and is recognized for its scientific
                                         expertise, flexible and responsive project management, and client service. WIL Research
                                         will also expand Charles River&rsquo;s existing business that provides services for agricultural
                                         and industrial chemical clients.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Diversifies
                                         portfolio</I></B><I> </I>&ndash; The acquisition of WIL Research will diversify Charles
                                         River&rsquo;s service portfolio by adding new specialty services in safety assessment
                                         and bioanalysis, as well as CDMO services. The broader portfolio will enable Charles
                                         River to increase the support it provides to biopharmaceutical clients worldwide across
                                         the early-stage drug research pipeline and expands the opportunities to partner with
                                         these clients.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enhances
                                         growth profile </I></B><I>&ndash; </I>The addition of WIL Research is expected to enhance
                                         Charles River&rsquo;s ability to achieve its long-term growth goals. The acquisition
                                         is also expected to generate attractive financial returns through profitable revenue
                                         growth and meaningful accretion to non-GAAP earnings per share.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Additional Financial and
Transaction Details</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In 2015, WIL Research is expected
to report annual revenue of approximately $215 million, an increase of approximately 9% over 2014 on a constant-currency basis.
The purchase price implies multiples of 12.9x non-GAAP EBITDA based on the estimated 2015 results, and approximately 11x non-GAAP
EBITDA based on the estimated 2016 results including operational synergies.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The transaction is expected to
close early in the second quarter of 2016, subject to regulatory approvals and customary closing conditions. Based on the anticipated
timing of the close, the acquisition is expected to add $150 to $170 million to Charles River&rsquo;s 2016 consolidated revenue,
and $240 to $250 million to 2017 consolidated revenue. It is also expected to be accretive to non-GAAP earnings per share by at
least $0.20 in 2016 and $0.45 to $0.50 in 2017. The Company expects to generate operational synergies as a result of the acquisition,
with benefits totaling $17 to $20 million within two years of closing. Items excluded from non-GAAP earnings per share are expected
to include all acquisition-related costs, which</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">primarily include amortization
of intangible assets, certain costs associated with efficiency initiatives, advisory fees, and certain third-party integration
costs.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The acquisition and associated
fees are expected to be financed through an expansion of Charles River&rsquo;s credit facility and cash. WIL Research is expected
to be reported primarily as part of Charles River&rsquo;s Discovery and Safety Assessment segment.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Wells Fargo Securities, LLC is
acting as the exclusive financial advisor to Charles River. Davis Polk &amp; Wardwell LLP is acting as Charles River&rsquo;s transactional
legal counsel and Axinn, Veltrop &amp; Harkrider LLP is acting as antitrust counsel. Harris Williams &amp; Co. is acting as the
lead financial advisor to WIL Research, with Houlihan Lokey serving as a co-advisor. King &amp; Spalding is acting as WIL Research&rsquo;s
transactional legal counsel and Arnold &amp; Porter LLP is acting as antitrust counsel.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Webcast</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Charles River Laboratories has
scheduled a live webcast on Thursday, January 7<SUP>th</SUP>, at 8:30 a.m. EST to discuss matters relating to this news release.
To participate, please go to <FONT STYLE="color: blue"><U>ir.criver.com</U></FONT> and select the webcast link. You can also find
the associated slide presentation on the website.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Charles River to Present
at 34<SUP>th</SUP> Annual J.P. Morgan Healthcare Conference</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Charles River Laboratories will
present at the 34<SUP>th</SUP> Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 12<SUP>th</SUP>,
at 10:30 a.m. PST (1:30&nbsp;p.m. EST), followed by a question and answer session at 11:00 a.m. PST (2:00 p.m. EST). Management
will present an overview of Charles River&rsquo;s strategic focus and business developments, including the intended acquisition
of WIL Research.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">A live webcast of the presentation
and the subsequent question and answer session will be available through a link that will be posted on the Investor Relations
section of the Charles River website <FONT STYLE="color: #303030">at </FONT><FONT STYLE="color: blue"><U>ir.criver.com</U></FONT>.
A webcast replay will be accessible through the same website approximately three hours after the presentation and will remain
available for approximately two weeks.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Use of Non-GAAP Financial
Measures</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This news release contains non-GAAP
financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets, certain
third-party integration costs, certain costs associated with efficiency initiatives, advisory fees, and other charges related
to our acquisitions and expenses associated with evaluating acquisitions. We exclude these items from the non-GAAP financial measures
because they are outside our normal operations. This news release also refers to our revenue in both a GAAP and non-GAAP (constant
currency) basis. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally
accepted accounting principles, and may be different than non-GAAP financial measures used by other companies.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In particular, we believe that
the inclusion of supplementary non-GAAP financial measures in this news release helps investors to gain a meaningful understanding
of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with
how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts.
We believe that the financial impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or
not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability
of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen irregularly
and the underlying costs associated with such activities do not recur on a consistent basis. Presenting revenue on a constant-currency
basis allows investors to measure our revenue growth exclusive of foreign currency exchange fluctuations more clearly. Non-GAAP
results also allow investors to compare the Company&rsquo;s operations against the financial results of other companies in the
industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this news release are not meant to
be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue
to periodically assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. A reconciliation
of the effect of this transaction on non-GAAP earnings per share for 2016 and 2017 to the most directly comparable GAAP financial
measure has not been included because it is impracticable to determine the allocation of the purchase price and other necessary
adjustments at this time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Caution Concerning Forward-Looking
Statements</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This news release includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified
by the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;outlook,&rdquo; and &ldquo;project&rdquo; and other similar expressions that
predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements include
statements in this news release regarding the acquisition of WIL Research, expectations regarding the timing of the closing of
the acquisition, and Charles River&rsquo;s expectations with respect to the impact of WIL Research on the Company, its service
offerings, client perception, revenue, revenue growth rates, and earnings; WIL Research&rsquo;s final 2015 reported financial
results; Charles River&rsquo;s projected future performance including revenue and earnings per share; Charles River&rsquo;s expected
operational synergies; as well as Charles River&rsquo;s future growth in the area of safety assessment and contract development
and manufacturing. Forward-looking statements are based on Charles River&rsquo;s current expectations and beliefs, and involve
a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from
those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the
ability to successfully complete the acquisition of WIL Research. A further description of these risks, uncertainties, and other
matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 17, 2015,
as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks
and uncertainties, actual results and events may differ materially from results and events</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">currently expected by Charles
River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release
except as required by law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About
Charles River</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Charles
River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading
academic institutions around the globe accelerate their research and drug development efforts.&nbsp; Our dedicated employees are
focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services,
visit <FONT STYLE="color: blue"><U>www.criver.com</U></FONT>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"># # #</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    Contact:</FONT></td>
    <TD STYLE="width: 14%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media
    Contact:</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    E. Hardy</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy
    Cianciaruso</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Vice President, Investor Relations</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Vice President, Public Relations</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">781.222.6190</FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">781.222.6168</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>susan.hardy@crl.com</U></FONT></td>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>amy.cianciaruso@crl.com</U></FONT></td></tr>
</table>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
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M)]]#HIU*<X*I2G"=-ZQG"2E&SZIQ;74O#\OZ5'H7^'];_,6@ H * "@ H *
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M=/>WN0TB-YO[L*0#[PH * "@ H * "@ ^G']* /@K]B;XW_$KXP^(OVIM/\
MB!KEOJ]K\,_CSX@\$>#8X-)TS2_[+\.6%Q?QVUE(^G6UN]\Z)!$#=7S3W3LK
M,TN'VJ ?>M !T]J-O(-O+\!-H],4E%)MI6OOT_X8+6\K;=+7#:!VQ^E.R[;?
MJ'R]-   Z#']* _#\/P# _+\.M'EMZ:6_P @V^7RW#:!VQC\,9HV_+L"5E9:
M+LM+?Y?(3:/3^8H2LK+1=MDO1=/D'DCY\U/3/VA&_:/\.ZMI?B#PS%^S7#X
MN[3Q'X:EAM#XJN/B";G53:W]M,VDO>C3EMWTA2L>LP0@PW.^SD+ABK)=++MV
M#^OZ1]"TP"@ H .E !^E !0 G3C!X_#K0 M 'PY^S( /VCOV[\#'_%VOAK[?
M\TFT$_S)/XT!MY6_"Y]QT % !0 4 % !T_SC% "?I[=*%Z6_KH&VVEOE:XM
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M[*-15O8U73ARI-0AS>ZI*-U'5IL]+_9O^-?CSXRZ[?)JT-E8:5X#\#Z'X?\
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M7OB!X4_L74IK^1=!U&>^DMQJBS6-G]COMMQ%YMM&;A%;>!,P + ;>1XMX_\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
